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 Influenza is a highly infectious respiratory disease that can impose significant 
health risks leading to increased morbidity and mortality. Annual influenza epidemics 
are estimated to contribute to approximately 3,000,000 to 5,000,000 cases of severe 
illness and approximately 250,000 to 500,000 deaths worldwide.1 In addition, annual 
influenza epidemics cause an average of 31.4 million outpatient clinic visits, 3.1 
million hospital admission days and more than 610,000 life-years lost in the United 
States (US).2 When consumer and societal costs are included, the annual economic 
burden in the US from influenza infections is estimated to be approximately $87.1 
billion.2 Receiving influenza vaccination is the most important and effective means of 
preventing the infection and its related complications. Pregnant women are now the 
highest priority group for vaccination as the physiological changes in pregnancy 
increase susceptibility to infection.3 However, the vaccination uptake rate among 
pregnant women has been unacceptably low. Many studies have shown that pregnant 
women are often not aware that they are at increased risk for influenza infection and 
should be vaccinated.4,5 Many health providers do not recommend that pregnant 
women receive the vaccine.6,7 This article reviews the complications of influenza 
infection for pregnant women, the fetus and the newborn infant. It also provides 
current recommendations for influenza vaccination for pregnant women, delineates 
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the factors influencing vaccine uptake and makes recommendations to increase 
vaccine uptake.   
 
INFLUENZA INFECTION DURING PREGNANCY 
Historical perspective 
The increased morbidity and mortality from influenza among pregnant women was 
first recognized in the influenza pandemics of 1916 to 19188 and 1957 to 1958.9 In 
one of the earliest studies, Harris8 observed a higher risk of complications from 
pneumonia due to influenza in pregnant women and increased mortality in the third 
trimester. During the 1957 global influenza pandemic, pregnant women had higher 
mortality rates from influenza-related pneumonia than non-pregnant women.9 A 
case-control study of over 25,000 US women from 1974 to 1993 showed that healthy 
pregnant women, irrespective of gestational age, had increased risk of hospitalization 
from cardiorespiratory illnesses.10 In a review of data from the 1975 to 1979 influenza 
seasons, researchers found that pregnant women had 2.3 times higher rates of 
outpatient consultations for acute respiratory diseases than non-pregnant women.11  
 
 In 2009, when a novel strain of influenza A/H1N1 virus was first identified in 
North America, there was a substantial impact on the general population. There were 
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xan estimated 70,000 hospital admissions, 9,700 Intensive Care Unit (ICU) 
admissions and 2,500 deaths attributable to A/H1N1 influenza infection within an 
eight-month period across 19 countries and administrative regions.12 The risk was 
higher in the young, the obese, and pregnant women. In a 2009 US study,13 the 
hospitalization rate among pregnant women from mid-April to mid-May, 2009 was 
estimated to be 0.32 per 100,000 which was 3.2 times higher than non-pregnant peers. 
In another study conducted from May to June 2009, a significantly higher morbidity 
rate was observed among pregnant women compared with non-pregnant peers.14 In 
the US, pregnant women were 7.1 times more likely to be hospitalized due to A/H1N1 
virus infection than non-pregnant women.14 Correspondingly, from June to August 
2009, there were a total of 722 ICU admissions in Australia and New Zealand due to 
A/H1N1 infection, among which 9.1% were pregnant women.15  
 
Physiologic changes of pregnancy 
Pregnant women are more vulnerable to respiratory illnesses than their non-pregnant 
peers because the pregnancy leads to physiological changes in the cardiopulmonary 
system as well as the immunological system.16 During pregnancy, women experience 
an increase in progesterone and beta-human chorionic gonadotropins.17 As pregnancy 
advances, there are alterations in the chest shape and dimensions and elevation of the 
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diaphragm. These changes contribute to increased dyspnea, increased oxygen 
consumption and tidal volume, and decreased functional residual capacity, all of 
which increase susceptibility to respiratory pathogens.17,18 Furthermore, to tolerate 
fetal antigens during pregnancy, evidence suggests that the maternal immune system 
suppresses cell-mediated immunity, which increases susceptibility to intracellular 
pathogens such as viruses and bacteria.19 Thus, as gestational age advances, the risk of 
serious morbidity and hospital admission from influenza infection increases 
substantially.10,20 Pregnant women who are hospitalized with influenza infection have 
significantly longer hospital stays, irrespective of gestational age21,22 and pregnant 
women with co-morbidities are more likely to be admitted to the ICU.23 
 
Adverse neonatal outcomes 
Women contracting infectious diseases during pregnancy are more likely to have 
adverse neonatal outcomes. In a 13-year Canadian population-based cohort study 
from 1990-2002, infants born to mothers who were hospitalized for respiratory illness 
were more likely to be small for gestational age. In addition, these infants were more 
likely to have a lower mean birth weight than infants whose mothers were 
hospitalized for reasons other than respiratory illness.24 A small study of pregnant 
women (n=41) infected with influenza during the 2009 A/H1N1 pandemic found a 
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significantly lower birth weight in infants of H1N1 infected mothers.25 Data from 
113,331 women in Norway showed that infants born to pregnant women infected with 
influenza had an almost two-fold greater risk of infant death than infants born to 
non-infected women.26 Teratogenic effects such as cleft lip and palate, neural-tube 
defects and cardiovascular malformations were 1.7 times to 3.2 times more common 
in infants born to mothers infected with influenza during the first trimester of 
pregnancy.27 Results from a national sample in Denmark found that there is an 
increased risk of schizophrenia associated with influenza infection during 
pregnancy.28 Results from a case-control study in California showed a 3- to 7-fold 
increase in schizophrenia in later life among the offspring of mothers who had 
influenza during pregnancy.29  
 
INFLUENZA VACCINATION DURING PREGNANCY 
 Healthy lifestyle practices, such as adequate hydration and nutrition and 
influenza vaccination, are the primary strategies to prevent influenza infection.30 In 
addition, adoption of personal protective measures, for example, proper use of face 
masks and frequent hand hygiene,31 are recommended to prevent the spread of 
respiratory infections. Influenza vaccination is widely considered to be the most 
effective preventive strategy, as it has a documented efficacy of about 90% in young, 
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healthy population groups.3 Two types of influenza vaccines are currently available, 
trivalent inactivated influenza vaccine (TIV) and live attenuated influenza vaccine 
(LAIV). TIV contains dead viruses and is administered by the intradermal or 
intramuscular route while LAIV contains weakened live viruses and is administered 
via the nasal route. TIV is recommended for pregnant women of any gestation age 
while LAIV should not be given during pregnancy because it contains live viruses.32 
Contraindications to influenza vaccination include a history of allergy to eggs or other 
vaccine components or a serious reaction to a previous dose of influenza vaccine.32 
Both TIV and LAIV are equally effective with minimal side effects and both vaccines 
are generally well tolerated. When the vaccine composition is well-matched with the 
circulating virus, it can offer up to 90% protection.33   
 
Vaccination recommendations 
To lower the number of medical consultations and the risk of hospitalization due to 
respiratory illnesses in pregnant women, as shown in table 1, most public health 
agencies and advisory groups recommend that women who are, or who will be 
pregnant during influenza season, receive influenza vaccination regardless of 
gestational age. In 2012, the World Health Organization (WHO) recommended that 
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pregnant women, regardless of gestational age, have the highest priority for seasonal 
influenza vaccination in national vaccination programs.3  
 
  
Benefits of vaccination 
Influenza vaccination is essential in public health programs aimed at decreasing 
seasonal influenza transmission and during pandemics.34 The vaccine is both 
cost-effective and safe. Influenza vaccine has a well established safety record and 
prevents excess doctors visits, hospitalizations and deaths resulting from influenza 
infection.32 Influenza vaccination during pregnancy is beneficial to both mothers and 
infants. A randomized controlled trial (RCT) conducted in Bangladesh demonstrated 
that influenza vaccination during pregnancy reduced respiratory illnesses among 
pregnant women by 36% and laboratory-confirmed influenza illnesses in infants up to 
six months old by 63%.35 In addition, during the peak influenza season, infants born 
to vaccinated mothers had a higher mean birth weight (200 grams) and were less 
likely to be born small for gestational age (25.9% versus 44.8%).36 Further evidence 
from a recent cohort of over 18,000 infants born to vaccinated mothers and a similar 
number of infants born to unvaccinated mothers, supported a 15-20% reduction in low 
birth weight, preterm birth and stillbirth in vaccinated mothers.37 
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When compared with older children, infants under six months old have higher 
hospital admission rates for influenza38 and higher influenza-associated mortality.39 
Data from a population-based, laboratory surveillance system in the United States (US) 
showed that from 2002 to 2009, infants <6 months of age born to vaccinated mothers 
were 45-48% less likely than infants of unvaccinated mothers to have influenza 
hospitalizations.40 Currently, no influenza vaccine is approved for infants less than six 
months of age. Thus immunization of pregnant women is important, not only to 
protect pregnant women but also to protect infants during the first six months of life.41 
 
Antiviral treatments 
At present, antiviral medications are recommended for use in critically ill patients 
infected with influenza. Neuraminidase inhibitors such as Oseltamivir (Tamiflu®) and 
Zanamivir (Relenza®) are recommended as first-line treatment.3 For highest 
effectiveness, it is generally recommended that antivirals be administered within the 
first 48 hours of the onset of illness.42 Amantadine and Rimantadine should not be 
used to treat influenza A infection because of a high level of drug resistance.43 
Although a low level of drug resistance (0.05%) has been observed for Oseltamivir 
and Zanamivir, both medications are still recommended as useful antiviral treatments 
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for influenza. Nevertheless, the potential for drug resistance will likely increase with 
broader use.43 The early detection and treatment of influenza in pregnant women is 
recommended to improve maternal outcomes.44 One study of 356 hospitalized 
pregnant women with influenza-like illness found that women requiring ICU 
admission were less likely to have been treated with antiviral medications within 48 
hours after illness onset.23 A recent Cochrane review (2012),45 however, found that 
there was no substantial evidence that either Oseltamivir or Zanamivir lowered the 
risk of complications from influenza infection such as pneumonia, influenza-related 
hospitalization or mortality. Given the clearly demonstrated efficacy and safety of the 
influenza vaccine in protecting both mothers and newborns against influenza infection, 
influenza vaccine should always be the first line of defense.3 
 
Vaccine safety 
In 1976, a total of 1,098 patients contracted Guillain-Barré Syndrome after 
vaccination against swine flu. Guillain-Barré syndrome is an uncommon 
inflammatory disorder of the peripheral nervous system causing muscle paralysis and 
respiratory failure and in severe cases, death may result.46 Thereafter, the US started a 
national surveillance program to monitor vaccine safety. From October 1976 to 
January 1977, the baseline attributable risk of Guillain-Barré syndrome resulting from 
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influenza vaccination was estimated at 1 per 100,000 vaccinations.47 In 2010, several 
federal surveillance systems began actively monitoring the safety of and adverse 
reactions to the influenza 2009 A/H1N1 monovalent vaccine in the US. From October 
2009 to March 2010, the incidence of Guillain-Barré syndrome was 1.92 per 100,000 
person-years among vaccinated persons which corresponds to 0.8 excess cases per 
1,000,000 seasonal influenza vaccinations.46 Therefore, although there is a potential 
risk of adverse reactions like Guillain-Barré syndrome, cases are very rare. 
 
 According to the Vaccine Adverse Event Reporting System (VAERS) in the US, 
there is no evidence of unusual pregnancy complications or adverse fetal outcomes 
from influenza vaccination during pregnancy.48 A recent retrospective cohort study 
reported that maternal influenza vaccination in the first trimester was not associated 
with any increase in congenital malformations.49 Approximately 15-20% of influenza 
vaccine recipients have mild, transient local reactions, such as redness and pain over 
the injection site, which generally resolves within one to two days.33 No vaccine is 
100% safe or effective.50 The risk from influenza infection is significantly greater than 
the risk of mild adverse reactions and the previously identified benefits of vaccination 
significantly outweigh the short-term, self-limiting side effects.3  Overall, there is 
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substantial evidence that the influenza vaccine is effective against influenza infection 
and is safe for pregnant women at any stage of pregnancy.51  
 
Prevalence of vaccination 
Despite the accumulated evidence of the safety and effectiveness of influenza 
vaccination during pregnancy, seasonal influenza vaccination uptake among pregnant 
women remains suboptimal.52 Recent studies have reported vaccination uptake rates 
ranging from 1.7%7,53 to 88.4%,54 but are often less than 20%.5,55 In the US, it was 
estimated that between 38-50% of pregnant women were vaccinated during the 
2010-2011 influenza season.56 Numerous studies have shown that pregnant women 
who refuse influenza vaccination generally underestimate the seriousness of influenza 
and are unaware of the increased susceptibility to influenza infection.5-7,55 In a 
cross-sectional study, nearly 90% of pregnant women perceived no difference in the 
risk of complications from influenza between pregnant women and non-pregnant 
women.57 A perception that the vaccine is not effective in preventing influenza is 
another barrier to vaccination5 and a history of uncomfortable side effects after 
vaccination discourage pregnant women from receiving the vaccine.58,59 
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 Lack of trust in the medical community and the health care system is an 
issue.60-62 One Canadian study reported that pregnant women who refused to be 
vaccinated believed that the vaccine had not been sufficiently tested.60 Studies in the 
US and Europe have reported that pregnant women explicitly refused vaccination 
because of distrust of the health care system.61,62 This perception could result from 
contradictory and confusing opinions in the medical community.63 On the other hand, 
vaccinated mothers were more likely to have confidence in the benefits of the 
vaccines and were more trustful of the health providers or the health care system.62,64 
 
 Concerns about the vaccine's safety and the possibility of birth defects were the 
predominant barrier to vaccination.4,5,57 In a Canadian study conducted during the 
2006-07 influenza season, 45% of participants perceived that the influenza 
vaccination was unsafe during pregnancy and nearly 80% believed that it could cause 
birth defects in newborns.57 Similarly, in a US study conducted during the A/H1N1 
pandemic, almost 60% of unvaccinated pregnant women were concerned about the 
vaccine safety5,57 Furthermore, as noted in Table 2, pregnant women had common 
misconceptions towards influenza infection and influenza vaccine. Many pregnant 
women perceive that they are not at risk of influenza4,6,59 and that the vaccine can 
cause influenza infection,65,66 is potentially harmful to the fetus67,68 and that effective 
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treatments for influenza infection are available.6,68 Studies have shown that 
primiparous pregnant women are more reluctant than multiparous women to receive 
the influenza vaccine.7,69 The first pregnancy can be stressful and anxiety provoking, 
and primiparous women may be especially concerned with the health and viability of 
fetus throughout pregnancy. Thus, primiparous pregnant women may be more 
reluctant to receive influenza vaccine fearing harm to the fetus.70 Overall, some 
pregnant women lack information concerning the risks of influenza infection versus 
the benefits of influenza vaccination to make them feel confident enough to be 
vaccinated.5  
 
The high morbidity and mortality rates among pregnant women due to 
A/H1N1 infection brought global attention to an issue that had previously largely 
been ignored. Although awareness about the consequences of a novel influenza strain 
were increased during the pandemic, there were concerns about the safety of the 
A/H1N1 vaccine as it was generally perceived by the public as a 'new' vaccine that 
had not been thoroughly tested.71 Hence, vaccination uptake among pregnant women 
against A/H1N1 infection was suboptimal. Reported vaccination rates were 6.2% in 
Hong Kong,5 6.9% in Australia,72 8.9% in Turkey,61 46.6% in the US,73 and 63% in 
the Netherlands.63 Subsequently, because the influenza A/H1N1 virus continues to be 
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the predominant circulating virus strain, it has been included in the trivalent seasonal 
influenza vaccine since 2010-2011 and it has been shown to be safe and highly 
effective.37  
 
Health provider recommendations 
Previous studies demonstrated that health provider recommendations were 
significantly associated with vaccination acceptance.4,63,74,75 However, researchers in 
the US, Australia and Hong Kong have reported that about 42-92% of pregnant 
women did not receive any vaccination recommendations from health providers and 
vaccination was not discussed.7,59,66,76 US studies have reported that some health 
providers may perceive that pregnant women are unwilling to be vaccinated.77-79 
Reluctance to recommend the vaccine could be due to liability concerns77 and to avoid 
perceived association between vaccination and spontaneous abortion or birth 
deficits.78 One US study found that health providers underestimated pregnant 
women’s susceptibility to influenza infection and had doubts about the benefit and 
effectiveness of the vaccine.80 Suboptimal influenza vaccination uptake in health 
providers has been observed in many studies81-83 and uptake varies substantially 
across health provider groups.84,85 Lack of knowledge about influenza infection and 
misconceptions about influenza vaccination were identified as the foremost reasons. 
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In contrast, vaccinated health providers are more likely to believe in the vaccine's 
safety and effectiveness, thus they are more willing to recommend it.86  
 
 While the 48-85% of US obstetricians surveyed provided influenza vaccine in 
their practice87,88 some obstetricians view vaccinating pregnant women as primarily 
the responsibility of family physicians.55,89 Health providers who demonstrate 
indifferent attitudes toward vaccination discourage pregnant women from seeking 
additional advice.90 Most studies examining health provider practices in vaccinating 
pregnant women have primarily focused on either obstetricians or family 
physicians.87,88,91,92 In one of the few studies involving nurses, midwives in Ontario, 
Canada in 200286  reported that health providers who had been vaccinated were more 
likely to recommend the vaccination to pregnant women. Furthermore, they believed 
that recommending vaccination was outside their scope of practice and that it was the 
doctor's primary responsibility to conduct such discussions. As pregnant women rely 
on health providers as information providers, who in many countries are primarily 
midwives, the inability to obtain the necessary information further decreases the 
chance that pregnant women will get vaccinated.90 Thus, a trustful relationship 




Increasing vaccination uptake 
Targeted interventions have been effective in enhancing influenza vaccination uptake 
among pregnant women.75,93 As noted in Table 3, reluctance to be vaccinated could be 
addressed by offering accurate information to counteract the misperceptions about the 
risk of influenza infection during pregnancy as well as to educate mothers about the 
safety and benefits of maternal influenza vaccination.76 Pregnant women can be 
informed that although local side effects are not uncommon and more serious adverse 
reactions following vaccine administration are rare.32 Vaccination rates could be 
increased to near 80% if vaccination was included as a component of antenatal care.93 
As pregnant women require regular antenatal care, health providers can use antenatal 
sessions as valuable therapeutic encounters to reinforce vaccination 
recommendations.94 Provision of a simple printed information leaflet during antenatal 
consultations has been effective in enhancing knowledge and improving vaccination 
uptake.95  
 
IMPLICATIONS FOR HEALTH PROVIDERS  
The role of health providers, especially perinatal nurses, midwives and 
obstetricians, is critical in promoting vaccine uptake, as they have extended contact 
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with pregnant women during antenatal visits. These visits provide an excellent 
opportunity to enhance pregnant women's knowledge of and accessibility to influenza 
vaccination.94 Studies have shown that midwives were more likely to recommend that 
pregnant women be vaccinated if they had been vaccinated.52,86 Thus, the vaccination 
rates of nurses and other health providers have implications for promoting the vaccine 
to pregnant women.52 At the administrative level, it may be necessary to reinforce that 
providing vaccination recommendations to pregnant women is within the scope of 
practice of most providers in high resource countries and one of the primary 
responsibilities.86 Recommending influenza vaccination to pregnant women is the 
responsibility of all health providers to protect mothers and infants.53,96 
  
 Many cross-sectional studies have examined predictors of influenza vaccination 
uptake among pregnant women.97 Recently, three RCTs have been conducted to 
improve prenatal vaccination rates, all in the US.98-100 Text message reminders were 
effective in increasing vaccine uptake in one study100 but failed to have any impact in 
another.99 A patient-centered education pamphlet was shown to be effective in 
improving both vaccination uptake and perceptions of the safety and benefit of 
influenza vaccination.98 Meanwhile, no published trials have been undertaken to 
evaluate the effectiveness of health providers' vaccination recommendation in 
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improving vaccination uptake in pregnant women. Thus, further high quality studies 
are recommended to evaluate the effectiveness of individual or multifaceted 
approaches to increase vaccine uptake. Research during the A/H1N1 pandemic has 
shown that public health education targeting of pregnant women can improve the 
uptake of both seasonal and pandemic influenza vaccines in this group.4,74 
 
CONCLUSION 
 Influenza infection is a serious global public health problem and vulnerable 
populations have been prioritized to receive the vaccination in order to lower the risk 
of influenza-related illness, hospitalization and mortality. Vaccination can prevent 
influenza infection during pregnancy, protect the fetus from the unintended 
consequences of infection, and protect newborns from respiratory infection during the 
first six months of life, a three-for-one benefit. Vaccination refusal is due to an 
underestimation of susceptibility to and the seriousness of influenza infection and the 
failure of health providers to recommend the vaccine. Vaccine promotion strategies 
that address the known barriers to vaccination have been effective in boosting the 
vaccination rate. Success in preventing morbidity and mortality from influenza 
infection in pregnant women cannot be accomplished without the combined efforts of 
public health officials, health care providers, and patients. 
 19 
References 
1. Influenza vaccination of women during pregnancy. 2008. 
http://www.who.int/vaccine_safety/topics/influenza/pregnancy/en/index.html. 
Accessed 8 June 2008. 
2. Molinari N-AM, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of 
seasonal influenza in the US: measuring disease burden and costs. Vaccine. 
2007;25(27):5086-5096. 
3. World Health Organization. Vaccines against influenza WHO position paper – 
November 2012. Wkly. Epidemiol. Rec. 2012(87):461-476. 
4. Kay MK, Koelemay KG, Kwan-Gett TS, Cadwell BL, Duchin JS. 2009 pandemic 
influenza A vaccination of pregnant women: King County, Washington State, 
2009-2010. Am. J. Prev. Med. 2012;42(6S2):S172-S179. 
5. Tarrant M, Wu KM, Yuen YSC, Cheung KL, Chan HSV. Determinants of 2009 
A/H1N1 influenza vaccination among pregnant women in Hong Kong. Matern Child 
Health J. 2013;17:23-32. 
6. SteelFisher GK, Blendon RJ, Bekheit MM, et al. Novel pandemic A (H1N1) influenza 
vaccination among pregnant women: motivators and barriers. Am. J. Obstet. Gynecol. 
2011;204(6):S116-S123. 
7. Yuen CYS, Fong DYT, Lee ILY, Sing C, Siu ESM, Tarrant M. Prevalence and 
predictors of maternal seasonal influenza vaccination in Hong Kong. Vaccine. 
2013;31(45):5281-5288. 
8. Harris JW. Influenza occurring in pregnant women: a statistical study of thirteen 
hundred and fifty cases. JAMA. 1919;72:978-980. 
9. Widelock D, Csazmas L, Klein S. Influenza, pregnancy, and fetal outcome. Public 
Health Rep. 1963;78(1):1-11. 
 20 
10. Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on 
acute cardiopulmonary hospitalizations in pregnant women. Am. J. Epidemiol. Dec 1 
1998;148(11):1094-1102. 
11. Mullooly JP, Barker WH, Nolan TF. Risk of acute respiratory disease among pregnant 
women during influenza A epidemics. Public Health Rep. Mar-Apr 
1986;101(2):205-211. 
12. Van Kerkhove MD, Vandemaele KAH, Shinde V, et al. Risk factors for severe 
outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. 
PLoS Medicine. 2011;8(7):1-12. 
13. Jamieson DJ, Honein MA, Rasmussen SA, et al. H1N1 2009 influenza virus infection 
during pregnancy in the USA. The Lancet. 2009;374:451-458. 
14. Creanga AA, Johnson TF, Graitcer SB, et al. Severity of 2009 pandemic influenza A 
(H1N1) virus infection in pregnant women. Obstet. Gynecol. 2010;115(4):717-726. 
15. The ANZIC Influenza Investigators. Critical care services and 2009 H1N1 influenza 
in Australia and New Zealand. NEJM. 2009;361(20):1925-1934. 
16. Shahab SZ, Glezen WP. Influenza virus. In: Gonik B, ed. Viral Diseases in 
Pregnancy. New York, NY: Springer-Verlag; 1994:215-223. 
17. Goodnight WH, Soper DE. Pneumonia in pregnancy. Crit. Care Med. 
2005;33(10(Suppl)):S390-S397. 
18. Bhatia P, Bhatia K. Pregnancy and the lungs. Postgrad. Med. J. 
2000;76(901):683-689. 
19. Jamieson DJ, Theiler RN, Rasmussen SA. Emerging Infections and pregnancy. 
Emerg. Infect. Dis. 2006;12(11):1638-1643. 
20. Dodds L, McNeil SA, Fell DB, et al. Impact of influenza exposure on rates of hospital 
admissions and physician visits because of respiratory illness among pregnant women. 
CMAJ. Feb 13 2007;176(4):463-468. 
 21 
21. Cox S, Posner SF, McPheeters M, Jamieson DJ, Kourtis AP, Meikle S. Influenza and 
pregnant women: hospitalization burden, United States, 1998-2002. J Womens Health 
(Larchmt). Oct 2006;15(8):891-893. 
22. Cox S, Posner SF, McPheeters M, Jamieson DJ, Kourtis AP, Meikle S. 
Hospitalizations with respiratory illness among pregnant women during influenza 
season. Obstet. Gynecol. Jun 2006;107(6):1315-1322. 
23. Varner MW, Rice MM, Anderson B, et al. Influenza-like illness in hospitalized 
pregnant and postpartum women during the 2009-2010 H1N1 pandemic. Obstet. 
Gynecol. 2011;118(3):593-600. 
24. McNeil SA, Dodds LA, Fell DB, et al. Effect of respiratory hospitalization during 
pregnancy on infant outcomes. Am. J. Obstet. Gynecol. 2011;Supplement to 
June:S54-S57. 
25. Mendez-Figueroa H, Raker C, Anderson BL. Neonatal characteristics and outcomes of 
pregnancies complicated by influenza infection during the 2009 pandemic. Am. J. 
Obstet. Gynecol. 2011;Supplement to June:S58-S63. 
26. Håberg SE, Trogstad L, Gunnes N, et al. Risk of fetal death after pandemic influenza 
virus infection or vaccination. NEJM. 16 January 2013 2013:1-8. 
27. Ács N, Bánhidy F, Puhó E, Czeizel AE. Maternal influenza during pregnancy and risk 
of congenital abnormalities in offspring. Birth Defects Research (Part A). 
2005;73:989-996. 
28. Byrne M, Agerbo E, Bennedsen B, Eaton WW, Mortensen PB. Obstetric conditions 
and risk of first admission with schizophrenia: a Danish national register based study. 
Schizophr. Res. 2007;97:5-59. 
29. Brown AS, Begg MD, Gravenstein S, et al. Serologic evidence of prenatal influenza in 
the etiology of schizophrenia. Arch. Gen. Psychiatry. August 1, 2004 
2004;61(8):774-780. 
 22 
30. Telford R, Rogers A. What infuences elderly peoples' decisions about whether to 
accept the infuenza vaccination? A qualitative study. Health Educ. Res. 
2003;18(6):743-753. 
31. Aiello AE, Murray GF, Perez V, et al. Mask use, hand hygiene, and seasonal 
influenza-like illness among young adults: a randomized intervention trial. J. Infect. 
Dis. 15 February 2010;201:491-498. 
32. Seasonal Influenza (Flu): Key Facts About Seasonal Flu Vaccine. 2014. 
http://www.cdc.gov/flu/protect/keyfacts.htm. Accessed 9 March 2014. 
33. Centers for Disease Control & Prevention. Chapter 11: Influenza. In: Atkinson W, 
Wolfe S, Hamborsky J, eds. Epidemiology and Prevention of Vaccine-Preventable 
Diseases. 12th Edition Second Printing (May 2012) ed. Washington DC: Public 
Health Foundation; 2012. 
34. Rasmussen SA, Jamieson DJ, Bresee JS. Pandemic influenza and pregnant women. 
Emerg. Infect. Dis. Jan 2008;14(1):95-100. 
35. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization 
in mothers and infants. N. Engl. J. Med. Oct 9 2008;359(15):1555-1564. 
36. Steinhoff MC, Omer SB, Roy E, et al. Neonatal outcomes after influenza 
immunization during pregnancy: a randomized controlled trial. CMAJ. 
2012;184(6):645-653. 
37. Källén B, Olausson PO. Vaccination against H1N1 influenza with Pandemrix® during 
pregnancy and delivery outcome: a Swedish register study. BJOG. 
2012;119(13):1583-1590. 
38. Nelson EAS, Ip M, Tam JS, et al. Burden of influenza infection in hospitalised 
children below 6 months of age and above in Hong Kong from 2005 to 2011. Vaccine. 
2014. 
 23 
39. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in 
the United States, 2003-2004. N. Engl. J. Med. 15 December 2005 
2005;353(24):2259-2567. 
40. Poehling KA, Szilagyi PG, Staat MA, et al. Impact of maternal immunization on 
influenza hospitalizations in infants. Am. J. Obstet. Gynecol. 2011:S141-S148. 
41. Benowitz I, Esposito DB, Gracey KD, Shapiro ED, Vázquez M. Influenza vaccine 
given to pregnant women reduces hospitalization due to influenza in their infants. 
Clin. Infect. Dis. 15 December 2010;51(12):1355-1361. 
42. Seasonal Influenza (Flu): What You Should Know About Flu Antiviral Drugs. 2014. 
http://www.cdc.gov/flu/antivirals/whatyoushould.htm. Accessed 9 March 2014. 
43. Centers for Disease Control & Prevention. Influenza activity - United States, 2012-13 
season and composition of the 2013-14 influenza vaccine. MMWR. June 14 
2013;62(23):473-479. 
44. Anderson BL, Rouse DJ, Fitzsimmons C. Clinical characteristics of pregnant women 
with influenza-like illness during the 2009 H1N1 pandemic and use of a standardized 
management algorithm. Am. J. Obstet. Gynecol. 2011;Supplement to June:S31-S37. 
45. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and 
treating influenza in healthy adults and children. Cochrane Database of Systematic 
Reviews. 2012(Issue 1):Art. No.:CD008965. 
46. Centers for Disease Control & Prevention. Preliminary results: surveillance for 
Guillain-Barré Syndrome after receipt of influenza A (H1N1) 2009 monovalent 
vaccine - United States, 2009-2010. MMWR. 2010;56(37):657-661. 
47. Schonberger LB, Bregman DJ, Sullivan-Boyyai JZ. Guillain-Barré syndrome 
following vaccination in the national influenza immunization program, United States, 
1976-1977. Am. J. Epidemiol. 1979;110(2):105-123. 
 24 
48. Moro PL, Broder K, Zheteyeva Y, et al. Adverse events in pregnant women following 
administration of trivalent inactivated influenza vaccine and live attenuated influenza 
vaccine in the Vaccine Adverse Event Reporting System, 1990-2009. Am. J. Obstet. 
Gynecol. 2011;204(146):e1-e7. 
49. Sheffield JS, Greer LG, Rogers VL, et al. Effect of influenza vaccination in the first 
trimester of pregnancy. Obstet. Gynecol. 2012;120:532-537. 
50. Vaccine Safety: History of Vaccine Safety. 2014. 
http://www.cdc.gov/vaccinesafety/vaccine_monitoring/history.html. Accessed 9 
March 2014. 
51. Munoz FM. Safety of influenza vaccines in pregnant women. Am. J. Obstet. Gynecol. 
2012;Supplement to September:s33-s37. 
52. Lu AB, Halim AA, Dendle C, et al. Influenza vaccination uptake amongst pregnant 
women and maternal care providers is suboptimal. Vaccine. 2012;30:4055-4059. 
53. Gracie S, Metcalfe A, Dolan SM, Kehler H, Siever J, Tough S. Utilization of the 2009 
H1N1 vaccine by pregnant women in a pandemic year. J Obstet Gynaecol Can. 
2011;33(2):127-133. 
54. Goldfarb I, Panda B, Wylie B, Riley L. Uptake of influenza vaccine in pregnant 
women during the 2009 H1N1 influenza pandemic. Am. J. Obstet. Gynecol. 
2011;204(6):S112-S115. 
55. Tong A, Biringer A, Ofner-Agostini M, Upshur R, McGeer A. A cross-sectional study 
of maternity care providers' and women's knowledge, attitudes, and behaviours 
towards influenza vaccination during pregnancy. J Obstet Gynaecol Can. May 
2008;30(5):404-410. 
56. Kennedy ED, Ahluwalia IB, Ding H, Lu PJ, Singleton JA, Bridges CB. Monitoring 
seasonal influenza vaccination coverage among pregnant women in the United States. 
Am. J. Obstet. Gynecol. 2012;207(3):S9-S16. 
 25 
57. Yudin MH, Salaripour M, Sgro MD. Pregnant women's knowledge of influenza and 
the use and safety of the influenza vaccine during pregnancy. J Obstet Gynaecol Can. 
Feb 2009;31(2):120-125. 
58. Ding H, Santibanez TA, Jamieson DJ, et al. Influenza vaccination coverage among 
pregnant women–National 2009 H1N1 Flu Survey (NHFS). Am. J. Obstet. Gynecol. 
2011;206(6):S96-S106. 
59. Ahluwalia IB, Jamieson DJ, Rasmussen SA, D'Angelo D, Goodman D, Kim H. 
Correlates of seasonal influenza vaccine coverage among pregnant women in Georgia 
and Rhode Island. Obstet. Gynecol. 2010;116:949-955. 
60. Fabry P, Gagneur A, Pasquier J-C. Determinants of A (H1N1) vaccination: 
cross-sectional study in a population of pregnant women in Quebec. Vaccine. 
2011;29:1824-1829. 
61. Ozer A, Arikan DC, Kirecci E, Ekerbicer HC. Status of pandemic influenza 
vaccination and factors affecting it in pregnant women in Kahramanmaras, an Eastern 
Mediterranean City of Turkey. PLoS ONE. 2010;5(12):e14177. 
62. Tucker Edmonds BM, Coleman J, Armstrong K, Shea JA. Risk perceptions, worry, or 
dstrust: what drives pregnant women's decisions to accept the H1N1 vaccine? 
Maternal and Child Health Journal. 2011;15:1203-1209. 
63. van Lier A, Steens A, Ferreira JA, van der Maas NAT, de Melker HE. Acceptance of 
vaccination during pregnancy: experience with 2009 influenza A (H1N1) in the 
Netherlands. Vaccine. 2012;30:2892-2899. 
64. Dlugacz Y, Fleischer A, Carney MT, et al. 2009 H1N1 vaccination by pregnant 
women during the 2009-10 H1N1 influenza pandemic. Am. J. Obstet. Gynecol. 
2012;206(339):e1-e8. 
65. Henninger M, Naleway A, Crane B, Donahue J, Irving S. Predictors of seasonal 
influenza vaccination during pregnancy. Obstet. Gynecol. 2013;121(4):741-749. 
 26 
66. Maher L, Hope K, Torvaldsen S, et al. Influenza vaccination during pregnancy: 
coverage rates and influencing factors in two urban districts in Sydney. Vaccine. 
2013;31(47):5557-5564. 
67. Fridman D, Steinberg E, Azhar E, Weedon J, Wilson TE, Minkoff H. Predictors of 
H1N1 vaccination in pregnancy. Am. J. Obstet. Gynecol. 2011;204(6):S124-S127. 
68. Centers for Disease Control & Prevention. Influenza vaccination coverage among 
pregnant women - United States, 2010-11 influenza season. Morb Mortal Wkly Rep. 
2011;60(32):1078-1082. 
69. Wu AC, Wisler-Sher DJ, Griswold K, et al. Postpartum mothers' attitudes, knowledge, 
and trust regarding vaccination. Maternal and Child Health Journal. 
2008;12:766-773. 
70. Yang YO, Peden-McAlpine C, Chen CH. A qualitative study of the experiences of 
Taiwanese women having their first baby after the age of 35 years. Midwifery Today 
Childbirth Educ. 2007;23:343-349. 
71. Drees M, Johnson O, Wong E, et al. Acceptance of 2009 H1N1 influenza vaccine 
among pregnant women in Delaware. Am. J. Perinatol. 2012;29(4):289-294. 
72. White SW, Petersen RW, Quinlivan JA. Pandemic (H1N1) 2009 influenza vaccine 
uptake in pregnant women entering the 2010 influenza season in Western Australia. 
Med. J. Aust. 2010;193:405-407. 
73. Centers for Disease Control & Prevention. Seasonal influenza and 2009 H1N1 
influenza vaccination coverage among pregnant women - 10 States, 2009-10 influenza 
season. Morb Mortal Wkly Rep. 2010;59(47):1541-1545. 
74. Centers for Disease Control & Prevention. Influenza vaccination coverage among 
pregnant women - 29 States and New York City, 2009-10 Season. Morb Mortal Wkly 
Rep. 24 February 2012;61(7):113-118. 
 27 
75. Mouzoon ME, Munoz FM, Greisinger AJ, et al. Improving influenza immunization in 
pregnant women and healthcare workers. Am J Managed Care. 2010;16(3):209-216. 
76. Panda B, Stiller R, Panda A. Influenza vaccination during pregnancy and factors for 
lacking compliance with current CDC guidelines. J Matern Fetal Neonatal Med. 
2011;24(3):402-406. 
77. Naleway AL, Smith WJ, Mullooly JP. Delivering influenza vaccine to pregnant 
women. Epidemiol. Rev. August 1, 2006 2006;28(1):47-53. 
78. Wallis DH, Chin JL, Sur DKC, Lee MY. Increasing rates of influenza vaccination 
during pregnancy: a multisite interventional study. Journal of the American Board of 
Family Medicine. Jul-Aug 2006;19(4):345-349. 
79. Gonik B, Jones T, Contreras D, Fasano N, Roberts C. The obstetrician-gynecologist's 
role in vaccine-preventable diseases and immunization. Obstet. Gynecol. Jul 
2000;96(1):81-84. 
80. Broughton DE, Beigi RH, Switzer GE, Raker CA, Anderson BL. Obstetric health care 
workers' attitudes and beliefs regarding influenza vaccination in pregnancy. Obstet. 
Gynecol. 2009;114(5):981-987. 
81. Maltezou HC, Maragos A, Halharapi T, Karagiannis I, Karageorgou K, Remoudaki H. 
Factors influencing influenza vaccination rates among healthcare workers in Greek 
hospitals. J. Hosp. Infect. 2007;66:156-159. 
82. Ehrenstein BP, Hanses F, Blaas S, Mandraka F, Audebert F, Salzberger B. Perceived 
risks of adverse effects and influenza vaccination: a survey of hospital employees. 
European Journal of Public Health. 2010;20(5):595-499. 
83. Lu PJ, Ding H, Black CL. H1N1 and seasonal influenza vaccination of U.S. healthcare 
personnel, 2010. Am. J. Prev. Med. 2012;43(3):282-292. 
 28 
84. Prematunge C, Corace K, McCarthy A, Nair RC, Pugsley R, Garber G. Factors 
influencing pandemic influenza vaccination of healthcare workers - a systematic 
review. Vaccine. 2012;30(32):4733-4743. 
85. Centers for Disease Control & Prevention. Health Care Personnel Flu Vaccination: 
Internet Panel Survey, United States, November 2012. 2012; 
http://www.cdc.gov/flu/pdf/fluvaxview/hcp-ips-nov2012-pdf.pdf. Accessed 26 August 
2013. 
86. Lee T, Saskin R, McArthur M, McGeer A. Beliefs and practices of Ontario midwives 
about influenza immunization. Vaccine. 2005;23(13):1574-1578. 
87. Power ML, Leddy MA, Anderson BL, Gall SA, Gonik B, Schulkin J. 
Obstetrician-gynecologists' practices and perceived knowledge regarding 
immunization. Am. J. Prev. Med. Sep 2009;37(3):231-234. 
88. Kissin DM, Power ML, Kahn EB, et al. Attitudes and practices of 
obstetrician-gynecologists regarding influenza vaccination in pregnancy. Obstet. 
Gynecol. 2011;118(5):1074-1080. 
89. Schrag SJ, Fiore AE, Gonik B, et al. Vaccination and perinatal infection prevention 
practices among obstetrician-gynecologists. Obstet. Gynecol. Apr 
2003;101(4):704-710. 
90. Meharry PM, Colson ER, Grizas AP, Stiller R, Vázquez M. Reasons why women 
accept or reject the trivalent inactivated influenza vaccine (TIV) during pregnancy. 
Maternal and Child Health Journal. 2013;17(1):156-164. 
91. Eppes C, Wu A, Cameron KA, Garcia P, Grobman W. Does obstetrician knowledge 
regarding influenza increase HINI vaccine acceptance among their pregnant patients? 
Vaccine. 2012;30(39):5782-5784. 
 29 
92. Ross DS, Rasmussen SA, Cannon MJ, et al. Obstetrician/gynecologists knowledge, 
attitudes, and practices regarding prevention of infections in pregnancy. J Womens 
Health (Larchmt). 2009;18(8):1187-1193. 
93. McCarthy EA, Pollock WE, Nolan T, Hay S, McDonald S. Improving influenza 
vaccination coverage in pregnancy in Melbourne 2010-2011. Aust. N. Z. J. Obstet. 
Gynaecol. 2012;52:334-341. 
94. Blondel B, Mahjoub N, Drewniak N, Launay O, Goffinet F. Failure of the vaccination 
campaign against A(H1N1) influenza in pregnant women in France: results from a 
national survey. Vaccine. 2012;30(8):5661-5665. 
95. Yudin MH, Salaripour M, Sgro MD. Impact of patient education on knowledge of 
influenza and vaccine recommendations among pregnant women. J Obstet Gynaecol 
Can. 2010;32(3):232-237. 
96. Canadian Nurses Association. Position Statement: Influenza Immunization of 
Registered Nurses. 2012; 
http://www2.cna-aiic.ca/cna/documents/pdf/publications/PS_Influenza_Immunization
_for_RNs_e.pdf. Accessed 26 August 2013. 
97. Yuen CYS, Tarrant M. Determinants of uptake of influenza vaccination among 
pregnant women – a systematic review. Vaccine. 2014;32:4602-4613. 
98. Meharry PM, Cusson RM, Stiller R, Vázquez M. Maternal influenza vaccination: 
evaluation of a patient-centered pamphlet designed to increase uptake in pregnancy. 
Maternal and Child Health Journal (Epub ahead of print). Sept 22 2013. 
99. Moniz MH, Hasley S, Meyn LA, Beigi RH. Improving influenza vaccination rates in 
pregnancy through text messaging: a randomized controlled trial. Obstet. Gynecol. 
2013;121(4):734-740. 
 30 
100. Stockwell MS, Westhoff C, Kharbanda EO, et al. Influenza vaccine text message 
reminders for urban, low-income pregnant women: a randomized controlled trial. Am. 
J. Public Health. 2014;Supplement 1:e7-e12. 
101. American College of Obstetricians and Gynecologists Committee on Obstetric 
Practice. ACOG Committee Opinion No. 468: Influenza vaccination during 
pregnancy. Obstet. Gynecol. 2010;116(4):1006-1007. 
102. Centers for Disease Control & Prevention. Guidelines for Vaccinating Pregnant 
women: abstracted from recommendations of the Advisory Committee on 
Immunization Practices (ACIP). 2013. 
103. American College of Nurse-Midwives. Position statement: immunization in pregnancy 
and postpartum. In: American College of Nurse-Midwives, ed2014. 
104. National Advisory Committee on Immunization. National Advisory Committee on 
Immunization (NACI): statement on seasonal influenza vaccine for 2013-2014. Can. 
Commun. Dis. Rep. 2013;39(ACS-4):1-32. 
105. National Health Service England. The national flu immunisation programme 2014/15. 
In: Health Do, ed. England2014. 
106. National Health and Medical Research Council. The Australian immunisation 
handbook, 10th ed. In: Ageing DoHa, ed: Australian Government; 2013:1-413. 
107. Centre for Health Protection. Scientific Committee on Vaccine Preventable Diseases: 
Recommendations on Seasonal Influenza Vaccination for the 2012/13 Season. In: 
Health Do, ed. Hong Kong: Centre for Health Protection,; 2012. 
108. European Commission. ECDC technical report: implementation of the Council 
recommendation on seasonal influenza vaccination (2009/1019/EU). Brussels2014. 
109. Klatt TE, Hopp E. Effect of a best-practice alert on the rate of influenza vaccination of 
pregnant women. Obstet. Gynecol. February 2012;119(2, Part 1):301-305. 
 31 
110. Wiley KE, Massey PD, Cooper SC, et al. Uptake of influenza vaccine by pregnant 
women: a cross-sectional survey. Med. J. Aust. 2013 Apr 15 2013;198(7):371-375. 
111. Bhaskar E, Thobias S, Anthony S, Kumar V, Navaneethan N. Vaccination rates for 
pandemic influenza among pregnant women: an early observation from Chennai, 
South India. Lung India. 2012;29(3): 232-235.
 32 
Table 1: Overview of vaccination recommendations for pregnant women 
Organization Country Recommendations Year Implemented 
American College of Obstetricians 
and Gynecologists101 
US  Influenza vaccination is recommended for all women who will be 
pregnant during the influenza season 
2010 
Centers for Disease Control & 
Prevention102 
US  Influenza vaccination is recommended for all women who are or 
will be pregnant (in any trimester) during the influenza season 
2013 
American College of 
Nurse-Midwives103 
US  Influenza vaccination is recommended for all pregnant women in 
any trimester 
2014 
National Advisory Committee on 
Immunization under Public Health 
Agency of Canada104 
Canada  Influenza vaccination is recommended for all pregnant women 
regardless of gestational age 
2013 
National Health Service105 England  Influenza vaccination is recommended for all pregnant women at 
any stage of pregnancy 
2014 
Australian Government 
Department of Health and 
Ageing106 
Australia  Influenza vaccination is recommended for all pregnant women at 
any stage of pregnancy, particularly those who will be in the 2nd or 
3rd trimester during the influenza season 
2013 
Centre for Health Protection107 Hong Kong  Influenza vaccination is recommended for all pregnant women  
 Pregnant women have the highest priority for vaccination 
2012 
World Health Organization3  Europe  Pregnant women should have the highest priority for vaccination 
 Pregnant women should be vaccinated with TIV at any stage of 
pregnancy 
2012 
European Commission108 Europe  A high number of Member States recommend vaccination for 
pregnant women 
 For 2011/12, 22 countries recommended the vaccination for all 
pregnant women; one country recommended the vaccination for 
pregnant women with an additional clinical indication 
 Thirteen countries recommended the vaccination at any stage of 
pregnancy; ten countries recommended vaccination in either the 
2nd or 3rd trimester. Five countries reported that vaccination was 
not recommended for this population 
2014 
TIV: Trivalent Inactivated Vaccine
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Table 2. Common myths and misconceptions about influenza and influenza vaccination 
during pregnancy 
Myth 1 Influenza is a mild disease6,59 
Myth 2 If necessary, influenza can be treated effectively with 
medication6,68 
Myth 3 The risk of influenza infection in pregnant women is the same as 
non-pregnant women4,57 
Myth 4 Healthy pregnant women do not need influenza vaccine4,6,71 
Myth 5 Influenza vaccine can cause influenza infection65,66 
Myth 6 Influenza vaccine during pregnancy can cause birth defects, 
miscarriage or preterm birth57,67,68 
Myth 7 
 
The risks associated with influenza vaccination during pregnancy 
are greater than the risks associated with influenza infection6 
Myth 8 
 
If you do not usually receive influenza vaccine, it is better not to 
receive the vaccination during pregnancy4,71 
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Table 3: Recommendations to improve influenza vaccination rates among pregnant women 
Recommendation 1 Assess vaccination status109 
Recommendation 2 Inform about the benefits and safety of the vaccine110 
Recommendation 3 Inform about the risks of influenza infection for pregnant 
women and infants65 
Recommendation 4 Involve the husband and/or family in the discussion of 
vaccination recommendations111 
Recommendation 5 Provide on-site influenza vaccination7,110 
Recommendation 6 If on-site vaccination is not available, provide a list of clinics 
or providers where the vaccine can be obtained111 
Recommendation 7 Provide printed materials to enhance the take-home message 
about the importance of vaccination95 
Recommendation 8 Send email or text message reminders to inform about the 
benefits, safety and availability of the vaccine100 
Recommendation 9 Place an alert reminder in the maternal record to remind 
HCPs to document vaccination status and reasons for 
vaccination refusal109 
Recommendation 10 Reassess vaccination status at each antenatal visit and 
postpartum109 
HCP: Health Care Provider 
 
 
 
